Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three‐factor model
Stefano Molica(Azienda Ospedaliera Pugliese Ciaccio), Francesca Romana Mauro(Sapienza University of Rome), Alessandra Tedeschi(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Livio Trentin(University of Padua), Massimo Gentile(Azienda Ospedaliera di Cosenza), Lorenzo De Paoli(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Luciano Levato(Azienda Ospedaliera Pugliese Ciaccio), Giovanni Del Poeta(University of Rome Tor Vergata), Marina Deodato(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Gianluigi Reda(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Luca Laurenti(Sapienza University of Rome), Marta Coscia(University of Turin), Gian Matteo Rigolin, Annalisa Chiarenza(University of Catania), Alessandro Noto(Fondazione IRCCS Istituto Nazionale dei Tumori), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Andrea Visentin(University of Padua), Caterina Stelitano(University of Reggio Calabria), Annamaria Giordano(University of Bari Aldo Moro), Roberta Murru, Antonio Cuneo(Arcispedale Sant'Anna), Stefania Ciolli(Azienda Ospedaliero-Universitaria Careggi), Anna Maria Frustaci(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Valerio Guarente(University of Perugia), Paolo Sportoletti(University of Perugia), Diana Giannarelli(Agostino Gemelli University Polyclinic), Claudia Ielo(Policlinico Umberto I), Robin Foà(Sapienza University of Rome), Candida Vitale(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino)
Cited by 10
Related Papers
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
|The Lancet|2009|665
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
|Annals of Oncology|2016|398
The coding genome of splenic marginal zone lymphoma: activation of <i>NOTCH2</i> and other pathways regulating marginal zone development
|The Journal of Experimental Medicine|2012|378